Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Vangeneugden · SciRah

Researcher profile · Semantic Scholar

T. Vangeneugden

Share profile

T. Vangeneugden — researcher profile on SciRah

h-index: 27
Works: 65
Citations: 3,618

Most-cited papers

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
J. Howard, V. Bril, T. Vu, C. Karam +12 more
2021Lancet Neurology531 citations Open access
Semantic Scholar
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
A. Nel, Neliëtte van Niekerk, S. Kapiga, L. Bekker +29 more
2016New England Journal of Medicine445 citations Open access
Semantic Scholar
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
R. Ortiz, E. Dejesus, H. Khanlou, E. Voronin +8 more
2008AIDS (London)391 citations Open access
Semantic Scholar
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
J. Madruga, D. Berger, M. McMurchie, F. Suter +9 more
2007The Lancet320 citations
Semantic Scholar
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
C. Katlama, R. Espósito, J. Gatell, J. Goffard +8 more
2007AIDS (London)184 citations Open access
Semantic Scholar
Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials
S. De Meyer, T. Vangeneugden, B. van Baelen, E. de Paepe +4 more
2008AIDS Research and Human Retroviruses155 citations
Semantic Scholar
Applying Concepts of Generalizability Theory on Clinical Trial Data to Investigate Sources of Variation and Their Impact on Reliability
T. Vangeneugden, A. Laenen, H. Geys, D. Renard +1 more
2005Biometrics109 citations
Semantic Scholar
Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3
J. Molina, C. Cohen, C. Katlama, B. Grinsztejn +7 more
2007Journal of Acquired Immune Deficiency Syndromes108 citations
Semantic Scholar
The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers
V. Sekar, D. Kestens, Sabrina Spinosa-Guzman, M. De Pauw +4 more
2007Journal of clinical pharmacology91 citations
Semantic Scholar
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96
K. Arastéh, P. Yeni, A. Pozniak, B. Grinsztejn +6 more
2009Antiviral Therapy83 citations
Semantic Scholar
Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements.
T. Vangeneugden, A. Laenen, H. Geys, D. Renard +1 more
2004Controlled Clinical Trials79 citations
Semantic Scholar
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
S. De Meyer, E. Lathouwers, I. Dierynck, E. de Paepe +6 more
2009AIDS (London)62 citations Open access
Semantic Scholar
50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209
G. Foster, C. Hézode, J. Bronowicki, G. Carosi +6 more
200960 citations
Semantic Scholar
10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS
Y. Benhamou, J. Moussalli, V. Ratziu, P. Lebray +7 more
200960 citations Open access
Semantic Scholar
Selection models and pattern‐mixture models to analyse longitudinal quality of life data subject to drop‐out
Bart Michiels, G. Molenberghs, L. Bijnens, T. Vangeneugden +1 more
2002Statistics in Medicine60 citations
Semantic Scholar
Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone
V. Sekar, F. Tomaka, E. Lefebvre, M. De Pauw +3 more
2011Journal of clinical pharmacology59 citations
Semantic Scholar
A unifying approach for surrogate marker validation based on Prentice's criteria
A. Alonso, G. Molenberghs, H. Geys, M. Buyse +1 more
2006Statistics in Medicine57 citations
Semantic Scholar
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
F. Debruyne, R. Murray, Y. Fradet, Jan E. Johansson +10 more
1998Urology55 citations
Semantic Scholar
Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers
V. Sekar, L. Lavreys, T. Van de Casteele, Cindy Berckmans +4 more
2010Antimicrobial Agents and Chemotherapy48 citations Open access
Semantic Scholar
Pharmacokinetic Interaction between Ethinyl Estradiol, Norethindrone and Darunavir with Low-Dose Ritonavir in Healthy Women
V. Sekar, E. Lefebvre, S. Guzmán, E. Felicione +3 more
2008Antiviral Therapy48 citations Open access
Semantic Scholar
Effects of ritonavir‐boosted darunavir vs. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers
F. Tomaka, E. Lefebvre, V. Sekar, B. van Baelen +3 more
2009HIV Medicine47 citations
Semantic Scholar
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
V. Sekar, E. Lefebvre, M. De Pauw, T. Vangeneugden +1 more
2008British Journal of Clinical Pharmacology39 citations Open access
Semantic Scholar
Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach
A. Alonso, H. Geys, G. Molenberghs, Michael G. Kenward +1 more
200435 citations
Semantic Scholar
Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
D. Renard, H. Geys, G. Molenberghs, T. Burzykowski +3 more
200334 citations
Semantic Scholar
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
T. Kakuda, A. Brochot, F. Tomaka, T. Vangeneugden +2 more
2014Journal of Antimicrobial Chemotherapy32 citations Open access
Semantic Scholar
Reliability of a Longitudinal Sequence of Scale Ratings
A. Laenen, A. Alonso, G. Molenberghs, T. Vangeneugden
200931 citations
Semantic Scholar
Marginal correlation from an extended random-effects model for repeated and overdispersed counts
T. Vangeneugden, G. Molenberghs, G. Verbeke, C. G. Demétrio
201129 citations
Semantic Scholar
Generalized reliability estimation using repeated measurements.
A. Laenen, T. Vangeneugden, H. Geys, G. Molenberghs
2006British Journal of Mathematical & Statistical Psychology27 citations
Semantic Scholar
Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects
V. Sekar, E. Lefebvre, T. De Marez, M. De Pauw +3 more
2008Clinical drug investigation26 citations
Semantic Scholar
Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements
A. Alonso, H. Geys, G. Molenberghs, M. Kenward +1 more
2003Biometrics26 citations
Semantic Scholar
Estimating Reliability and Generalizability from Hierarchical Biomedical Data
G. Molenberghs, A. Laenen, T. Vangeneugden
2007Journal of Biopharmaceutical Statistics25 citations
Semantic Scholar
INVESTIGATING THE CRITERION VALIDITY OF PSYCHIATRIC SYMPTOM SCALES USING SURROGATE MARKER VALIDATION METHODOLOGY
A. Alonso, H. Geys, G. Molenberghs, T. Vangeneugden
2002Journal of Biopharmaceutical Statistics25 citations
Semantic Scholar
Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone.
A. Camacho, R. Eggo, N. Goeyvaerts, A. Vandebosch +6 more
2017Vaccine24 citations Open access
Semantic Scholar
Darunavir/Ritonavir Pharmacokinetics Following Coadministration With Clarithromycin in Healthy Volunteers
V. Sekar, Sabrina Spinosa-Guzman, E. Paepe, M. Pauw +3 more
2008Journal of clinical pharmacology22 citations
Semantic Scholar
Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers
V. Sekar, E. Lefebvre, T. De Marez, Sabrina Spinosa-Guzman +4 more
2007Drugs in R&D21 citations
Semantic Scholar
Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers
V. Sekar, E. Lefebvre, Kris Mariën, M. De Pauw +2 more
2007Therapeutic Drug Monitoring20 citations
Semantic Scholar
A Unified Approach to Multi‐item Reliability
A. Alonso, A. Laenen, G. Molenberghs, H. Geys +1 more
2010Biometrics17 citations
Semantic Scholar
Marginal Correlation in Longitudinal Binary Data Based on Generalized Linear Mixed Models
T. Vangeneugden, G. Molenberghs, A. Laenen, H. Geys +2 more
201016 citations
Semantic Scholar
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
V. Sekar, E. Lefebvre, Kris Mariën, M. De Pauw +3 more
2009British Journal of Clinical Pharmacology13 citations Open access
Semantic Scholar
Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
A. Hill, D. Miralles, T. Vangeneugden, E. Lefebvre
2007AIDS (London)12 citations
Semantic Scholar
Validation of biomarkers as surrogates for clinical endpoints
M. Buyse, T. Vangeneugden, L. Bijnens, D. Renard +3 more
200312 citations
Semantic Scholar
Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales.
A. Laenen, A. Alonso, G. Molenberghs, T. Vangeneugden +1 more
2009Journal of Psychiatric Research11 citations
Semantic Scholar
A family of measures to evaluate scale reliability in a longitudinal setting
A. Laenen, A. Alonso, G. Molenberghs, T. Vangeneugden
200911 citations
Semantic Scholar
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges
A. Vandebosch, R. Mogg, N. Goeyvaerts, C. Truyers +5 more
2016Clinical Trials10 citations Open access
Semantic Scholar
Pharmacokinetics of darunavir after administration of an oral suspension with low‐dose ritonavir and with or without food
T. Kakuda, V. Sekar, L. Lavreys, E. de Paepe +4 more
2014Clinical pharmacology in drug development10 citations
Semantic Scholar
Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients
Dénes Bánhegyi, Christine Katlama, C. D. da Cunha, S. Schneider +7 more
2008Journal of the International AIDS Society10 citations Open access
Semantic Scholar
Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)
James F. Howard, Vera Bril, Tuan Vu, C. Karam +8 more
2021Neurology7 citations
Semantic Scholar
Coping With Memory Effect and Serial Correlation When Estimating Reliability in a Longitudinal Framework
A. Laenen, A. Alonso, G. Molenberghs, T. Vangeneugden +1 more
20105 citations
Semantic Scholar
Generalizability in NonGaussian Longitudinal Clinical Trial Data Based on Generalized Linear Mixed Models
T. Vangeneugden, G. Molenberghs, A. Laenen, A. Alonso +1 more
2008Journal of Biopharmaceutical Statistics4 citations
Semantic Scholar
Phase 2 study of Telaprevir administered Q8 or Q12H with Peginterferon-Alfa-2A or Alfa-2B and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results
X. Forns, P. Marcellin, T. Goeser, P. Ferenci +8 more
20084 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Molenberghs×19
Invite
G. Molenberghs — researcher profile on SciRah
E. Lefebvre×16
Invite
E. Lefebvre — researcher profile on SciRah
H. Geys×12
Invite
H. Geys — researcher profile on SciRah
V. Sekar×12
Invite
V. Sekar — researcher profile on SciRah

×12

Invite

R. Hoetelmans — researcher profile on SciRah

Invite

M. De Pauw — researcher profile on SciRah

Invite

A. Laenen — researcher profile on SciRah

Invite

A. Alonso — researcher profile on SciRah

Sabrina Spinosa-Guzman×8

Invite

Sabrina Spinosa-Guzman — researcher profile on SciRah

Invite

F. Tomaka — researcher profile on SciRah

Invite

E. de Paepe — researcher profile on SciRah

Invite

S. De Meyer — researcher profile on SciRah